Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.31, $0.23 better than the analyst estimate of $4.08. Revenue for the quarter came in at $600.89 million versus the consensus estimate of $577.58 million.

"We delivered strong financial results this quarter, with increasingly diversified revenues fueled by the recent launch of Zepzelca, an innovative new treatment for relapsed small cell lung cancer, which we expect to be a catalyst for significant growth in our oncology portfolio. During 2020, we are demonstrating our operational agility as we navigate through the COVID-19 pandemic and deliver on a set of critically important objectives," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "This is a transformative year for Jazz and today marks our third product launch in 2020, keeping us on track to execute up to five key launches through 2020 and 2021. We continue to build upon our strong foundation by investing in assets to further diversify and expand our innovative neuroscience and oncology pipelines. We are excited about the opportunities ahead to deliver life-changing therapies for patients and drive enhanced shareholder value."

Robert Iannone, M.D., M.S.C.E., executive vice president, research and development, of Jazz Pharmaceuticals added, "We achieved multiple key R&D objectives in the third quarter, highlighted by FDA approval of Xywav in narcolepsy. We are encouraged by compelling top-line data for JZP-258 in idiopathic hypersomnia and are preparing to submit our supplemental NDA in the first quarter of 2021. With the significant progress and successes in our regulatory and R&D operations this year, we are poised to bring multiple new and highly differentiated treatment options to patients in areas of high unmet medical need."

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.